Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

NCT01285765 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

650

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: RCHOP21

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]